Identifying precancerous multiple myeloma in African American adults
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
This study is testing a way to find early signs of multiple myeloma in Black and African American adults aged 30 and older to help catch it sooner and improve their health outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1665 (estimated) |
| Ages | 30 Years and up |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Charlotte, North Carolina) |
| Trial ID | NCT06644625 on ClinicalTrials.gov |
What this trial studies
The CHAAMP Internal Pilot aims to identify multiple myeloma at the precancerous stage of monoclonal gammopathy of undetermined significance (MGUS) in Black and/or African American adults aged 30 and older. Over a one-year period, participants residing in Charlotte, NC, will be screened for MGUS, with a target enrollment of 1665 individuals. Those who test positive will receive referrals for further diagnostic evaluation and may consent to a longitudinal follow-up for up to 10 years. The study seeks to reduce the risk of delayed diagnosis and improve long-term outcomes for participants.
Who should consider this trial
Good fit: Ideal candidates are Black and/or African American adults aged 30 years or older living in Charlotte, NC, who are willing to participate in screening.
Not a fit: Patients with a self-reported history of MGUS, smoldering multiple myeloma, or other related plasma cell disorders will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better management of multiple myeloma, ultimately improving patient outcomes.
How similar studies have performed: Other studies have shown success in early detection of multiple myeloma through screening, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
SCREENING Inclusion Criteria: * Age 30 years or older at the time of consent * Either: 1. Self-identify as Black and/or African American OR 2. First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia * Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately * Reside in Charlotte, NC, or the surrounding area, based on self-report SCREENING Exclusion Criteria: * Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS. LONGITUDINAL Inclusion Criteria: * Test positive for monoclonal gammopathy during screening portion of the study * Consent to the longitudinal portion of the study LONGITUDINAL Exclusion Criteria: * The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.
Where this trial is running
Charlotte, North Carolina
- Atrium Health Levine Cancer — Charlotte, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Manisha Bhutani, MD — Atrium Health Wake Forest Baptist Comprehensive Cancer Center
- Study coordinator: Margarita Dzhanumova
- Email: margarita.dzhanumova@atriumhealth.org
- Phone: 704-754-3768
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.